Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Accumulated Expenses: 2018-2025

Historic Accumulated Expenses for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to $19.4 million.

  • Arcturus Therapeutics Holdings' Accumulated Expenses fell 40.17% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year decrease of 40.17%. This contributed to the annual value of $38.8 million for FY2024, which is 21.64% up from last year.
  • Arcturus Therapeutics Holdings' Accumulated Expenses amounted to $19.4 million in Q3 2025, which was down 21.30% from $24.6 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Accumulated Expenses high stood at $52.4 million for Q3 2021, and its period low was $19.4 million during Q3 2025.
  • Over the past 3 years, Arcturus Therapeutics Holdings' median Accumulated Expenses value was $31.9 million (recorded in 2023), while the average stood at $30.7 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 258.61% in 2021, then slumped by 51.24% in 2022.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' Accumulated Expenses stood at $23.5 million in 2021, then increased by 28.52% to $30.2 million in 2022, then grew by 5.45% to $31.9 million in 2023, then rose by 21.64% to $38.8 million in 2024, then slumped by 40.17% to $19.4 million in 2025.
  • Its Accumulated Expenses stands at $19.4 million for Q3 2025, versus $24.6 million for Q2 2025 and $30.6 million for Q1 2025.